Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred R Hirsch

Showing results (131-140 of 407) with videos related to

Pageof 41
Sort By:
Lancet (London, England)|August 9, 2024
New promises and challenges in the treatment of advanced non-small-cell lung cancerMay-Lucie Meyer, Bailey G Fitzgerald, Luis Paz-Ares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapyPaul A Bunn, Rafal Dziadziuszko, Marileila Varella-Garcia, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
c-MET as a biomarker in patients with surgically resected non-small cell lung cancerGeorgios Tsakonas, Johan Botling, Patrick Micke, et al.
Critical Reviews in Oncology/Hematology|May 30, 2024
Rediscovering immunohistochemistry in lung cancerAnna La Salvia, May-Lucie Meyer, Fred R Hirsch, et al.
Nature Reviews. Clinical Oncology|January 6, 2025
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questionsYibei Wang, Mohammed Safi, Fred R Hirsch, et al.
Clinical Lung Cancer|March 27, 2007
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategiesDavid R Gandara, Angela M Davies, Oliver Gautschi, et al.
Oncotargets and Therapy|December 22, 2017
Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodulesYayi He, Yang Yang, Peng Kuang, et al.
Lancet (London, England)|August 31, 2016
Lung cancer: current therapies and new targeted treatmentsFred R Hirsch, Giorgio V Scagliotti, James L Mulshine, et al.
Cancer|March 6, 2015
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)Nasser H Hanna, Suzanne E Dahlberg, Jill M Kolesar, et al.
Oncotargets and Therapy|May 5, 2016
Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastasesYayi He, Wenwen Sun, Yan Wang, et al.
Pageof 41

Showing results (131-140 of 407) with videos related to

Sort By:
Pageof 41
Lancet (London, England)|August 9, 2024
New promises and challenges in the treatment of advanced non-small-cell lung cancerMay-Lucie Meyer, Bailey G Fitzgerald, Luis Paz-Ares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapyPaul A Bunn, Rafal Dziadziuszko, Marileila Varella-Garcia, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
c-MET as a biomarker in patients with surgically resected non-small cell lung cancerGeorgios Tsakonas, Johan Botling, Patrick Micke, et al.
Critical Reviews in Oncology/Hematology|May 30, 2024
Rediscovering immunohistochemistry in lung cancerAnna La Salvia, May-Lucie Meyer, Fred R Hirsch, et al.
Nature Reviews. Clinical Oncology|January 6, 2025
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questionsYibei Wang, Mohammed Safi, Fred R Hirsch, et al.
Clinical Lung Cancer|March 27, 2007
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategiesDavid R Gandara, Angela M Davies, Oliver Gautschi, et al.
Oncotargets and Therapy|December 22, 2017
Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodulesYayi He, Yang Yang, Peng Kuang, et al.
Lancet (London, England)|August 31, 2016
Lung cancer: current therapies and new targeted treatmentsFred R Hirsch, Giorgio V Scagliotti, James L Mulshine, et al.
Cancer|March 6, 2015
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)Nasser H Hanna, Suzanne E Dahlberg, Jill M Kolesar, et al.
Oncotargets and Therapy|May 5, 2016
Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastasesYayi He, Wenwen Sun, Yan Wang, et al.
Pageof 41